scholarly journals Will the advances in our understanding of mucosal immunology contribute to improvements in clinical control of IBD?

2011 ◽  
Vol 4 (2) ◽  
pp. 126-126
Keyword(s):  
Mucosal Immunology ◽  
Clinical Control

Endovenous radiofrequency powered segmental thermal ablation (Closure FAST) of great saphenous veins

Phlebologie ◽  
2010 ◽  
Vol 39 (02) ◽  
pp. 69-71 ◽  
Author(s):  
T. M. Proebstle ◽  
Keyword(s):  
Side Effects ◽  
Thermal Ablation ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Duplex Ultrasound ◽  
Multicenter Trial ◽  
Saphenous Veins ◽  
Clinical Control ◽  
Prospective Multicenter Trial

Summary Background: Radiofrequency powered segmental thermal ablation Closure FAST has become a globally engaged technology for ablation of incompetent great saphenous veins (GSVs). Mid-term results of slowly resolving side effects are still not described. Methods: RSTA-treated GSVs (n = 295) were followed for 24 months in a prospective multicenter trial. Clinical control visits included flow and reflux analysis by duplex-ultrasound and assessment of treatment related side effects at all times. Results: 280 of 295 treated GSVs (94.9%) were available for 24 months follow-up. According to the method of Kaplan and Meier at 24 months after the intervention 98.6% of treated legs remained free of clinically relevant axial reflux. The average VCSS score improved from 3.9 ± 2.1 at screening to 0.7 ± 1.2 at 24 months follow-up (p < 0.0001). While only 41.1% of patients were free of pain before treatment, at 24 months 99.3% reported no pain and 96.4% did not experience pain during the 12 months before. At 24 months n=3 legs showed pigmentation along the inner thigh and one leg showed study-treatment related paresthesia. Conclusion: Radiofrequency powered segmental thermal ablation Closure FAST showed a very moderate side-effect profile in conjunction with a high and durable clinical success rate.

Growth hormone levels in diabetes. Correlation with the clinical control of the disease

Diabetes ◽  
1976 ◽  
Vol 25 (3) ◽  
pp. 167-172 ◽  
Author(s):  
R. Vigneri ◽  
S. Squatrito ◽  
V. Pezzino ◽  
S. Filetti ◽  
S. Branca ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Levels ◽  
Clinical Control

Mucosal Immunology and Probiotics

2012 ◽  
Vol 13 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Maria Luisa Dongarrà ◽  
Valeria Rizzello ◽  
Letizia Muccio ◽  
Walter Fries ◽  
Antonio Cascio ◽  
...  
Keyword(s):  
Mucosal Immunology

Taming trilostane: past and future

2019 ◽  
Vol 24 (9) ◽  
pp. 458-465
Author(s):  
Constance N White
Keyword(s):  
Adrenocorticotropic Hormone ◽  
Monitoring Tool ◽  
Acth Stimulation ◽  
Monitoring Therapy ◽  
Clinical Control ◽  
Cortisol Levels

A number of methods have been proposed for monitoring trilostane therapy for canine hyperadrenocorticism. Lack of consensus on timing and targets for adrenocorticotropic hormone (ACTH) stimulation testing, coupled with the fact that post-ACTH cortisol levels may not correlate well with clinical control, suggest that stimulation testing may not be as reliable a monitoring tool as initially thought. This article reviews developments in our understanding of the action, dosage, and monitoring of trilostane therapy of canine hyperadrenocorticism. Trilostane pharmacodynamics should be considered both in monitoring therapy and in tailoring dosage and frequency of administration.

scholarly journals COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Myriam Calle Rubio ◽  
◽  
Juan Luis Rodriguez Hermosa ◽  
Juan P. de Torres ◽  
José María Marín ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Clinical Status ◽  
Airflow Limitation ◽  
Psychological Status ◽  
Prognostic Information ◽  
Clinical Control ◽  
All Cause Mortality ◽  
Long Term Follow Up

Abstract Background Control in COPD is a dynamic concept that can reflect changes in patients’ clinical status that may have prognostic implications, but there is no information about changes in control status and its long-term consequences. Methods We classified 798 patients with COPD from the CHAIN cohort as controlled/uncontrolled at baseline and over 5 years. We describe the changes in control status in patients over long-term follow-up and analyze the factors that were associated with longitudinal control patterns and related survival using the Cox hazard analysis. Results 134 patients (16.8%) were considered persistently controlled, 248 (31.1%) persistently uncontrolled and 416 (52.1%) changed control status during follow-up. The variables significantly associated with persistent control were not requiring triple therapy at baseline and having a better quality of life. Annual changes in outcomes (health status, psychological status, airflow limitation) did not differ in patients, regardless of clinical control status. All-cause mortality was lower in persistently controlled patients (5.5% versus 19.1%, p = 0.001). The hazard ratio for all-cause mortality was 2.274 (95% CI 1.394–3.708; p = 0.001). Regarding pharmacological treatment, triple inhaled therapy was the most common option in persistently uncontrolled patients (72.2%). Patients with persistent disease control more frequently used bronchodilators for monotherapy (53%) at recruitment, although by the end of the follow-up period, 20% had scaled up their treatment, with triple therapy being the most frequent therapeutic pattern. Conclusions The evaluation of COPD control status provides relevant prognostic information on survival. There is important variability in clinical control status and only a small proportion of the patients had persistently good control. Changes in the treatment pattern may be relevant in the longitudinal pattern of COPD clinical control. Further studies in other populations should validate our results. Trial registration: Clinical Trials.gov: identifier NCT01122758.

Sign in / Sign up

Export Citation Format

Share Document